AI filing briefs · archive

8-K filings in April 2024, explained

188 material Form 8-K filings that 175 companies we cover made with the SEC in April 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

1 of 188 briefs matches

newest first · times in ET

TECHBIO-TECHNE Corp Apr 30, 4:30 PM ET

Bio-Techne appoints Dr. Judith Klimovsky to board as independent director

Neutral leadership Written later 5.02 8.01

Bio-Techne expanded its board from ten to eleven members on April 24, 2024, and appointed Dr. Judith Klimovsky, currently Executive Vice President and Chief Development Officer at Genmab, as an independent director. The filing also discloses a one-year waiver of the board's mandatory retirement policy for Dr. Roeland Nusse. The change is a board governance update with no financial figures reported.

Dr. Judith Klimovsky appointed as independent director effective April 24, 2024, to the Science and Technology Committee
Board temporarily expanded from ten to eleven members, ten of whom are independent
Board approved a one-year waiver of mandatory retirement policy for Dr. Roeland Nusse

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.